New weight-loss jabs could help boost the economy in Britain by getting people “back into work”, the Prime Minister has said.
Wylie said: "Ozempic (semaglutide) is a medication licensed for the management of type 2 diabetes. While it has shown ...
Researchers reveal the importance of personalized communication and side effect management in improving outcomes for patients ...
GLP-1 agonists work by suppressing patients’ appetites and have been approved to treat obesity and type 2 diabetes in the ...
Nearly a quarter-of-a-million people are expected to receive the Mounjaro jab over the next three years. NHS officials have ...
Researchers find that Semaglutide improves cognitive function and reduces amyloid and tau pathology in Alzheimer's disease ...
Recent studies have shown that pharmacologic weight loss with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and combination therapies is approaching magnitudes achieved with surgery. However, ...
Ozempic is in a class of medication called GLP-1, or glucagon-like peptide 1, agonists, which are primarily used to ...
GlobalData’s report assesses the drugs in the Glucagon Like Peptide 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.
Drugs like Ozempic and Wegovy may provide a surprising, life-saving benefit for the youngest patients taking these diabetes and weight loss medications.
Most digital health purchasers plan to increase their investments next year and are asking for risk-based contracts.
Speakers from across the care continuum will discuss legislative updates, glucagon-like peptide-1 (GLP-1) use for weight management, and more at this year’s AMCP Nexus.